NA
AXSM icon

NewEdge Advisors’s Axsome Therapeutics AXSM Stock Holding History

NewEdge Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50
Closed -$9.13K – 4150
2025
Q4 		$9.13K Buy
+50
New +$6.98K ﹤0.01% 3496
2023
Q1 		– Sell
-100
Closed -$7.71K – 3470
2022
Q4 		$7.71K Buy
+100
New +$5.98K ﹤0.01% 2451

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NewEdge Advisors's AXSM Position: Q1 2026 in Review

NewEdge Advisors sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 50 shares — an estimated $9.13K sold.

NewEdge Advisors first reported a position in AXSM in Q4 2022 and held it in 2 quarters. The position peaked at $9.13K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • NewEdge Advisors reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
  • NewEdge Advisors sold 50 Axsome Therapeutics shares in Q1 2026, an estimated $9.13K.
  • NewEdge Advisors first reported a position in Axsome Therapeutics in Q4 2022 and held it in 2 quarters.
  • NewEdge Advisors's Axsome Therapeutics position peaked at $9.13K in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.